gastric cancer, pancreatic cancer
Conditions
Interventions
5-ALA is administrated 2-4 hours before operation orally. We perform standard approach operation. First, after removing the lymph nodes, we examine PDD with fluorescent observation. Second, we rand
Sponsors
Hokkaido University Graduate School of Medicine Gastroenterological Surgery II
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients above 20 years old. Patients have malignant tumor lesions in the stomach or pancreas. Patients who provided signed informed consent.
Exclusion criteria
Exclusion criteria: Patients with a history of hypersensitivity of 5-ALA or porphyrins Porphyria Patients taking drugs that may cause photosensitivity Patients who is or might be pregnant Patients who have liver dysfunction Patients who have kidney dysfunction Patients who have ischemic heart disease Patients who are during lactation or hope becoming pregnant Patients who is determined inappropriate to participate in the study by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The accuracy of positive rate of the lymph node metastasis using the spectroscopy. | — |
Secondary
| Measure | Time frame |
|---|---|
| We evaluate the lymph nodes, the main tumor and the other lesions suspected metastasis to the following items. *The diagnosability by spectroscopy, fluorescent observation and white light observation. *The relationship between histological type and spectrum. *The relationship between tumor volume and spectrum. *The appropriate cut off value of fluorescent intensity. *The effectiveness of the spectroscope compared with VLD-EX(SBI Pharma). | — |
Countries
Japan
Contacts
Public ContactYuma Ebihara
Hokkaido University Graduate School of Medicine Gastroenterological Surgery II
Outcome results
None listed